Artificial transcription factors can be engineered to interact with specific DNA sequences to modulate endogenous gene expression within cells. A significant hurdle to implementation of this approach is the selection of the appropriate DNA sequence for targeting. We reasoned that a good target site should be located in chromatin, where it is accessible to DNA-binding proteins, and it should be in the close vicinity of known transcriptional regulators of the gene. Here we have explored the efficacy of these criteria to guide our selection of potential regulators of ␥-globin expression. Several zinc finger-based transcriptional activators were designed to target the sites proximal to the ؊117-position of the ␥-globin promoter. This region is proximal to the binding sites of known and potential natural transcription factors. Design and study of three transcription factors identified the potent transcriptional activator, gg1-VP64-HA. This transcription factor was able to interact directly with the ␥-globin promoter and upregulate expression of reporter gene constructs as well as the endogenous gene in a selective manner. Transfection of a gg1-VP64-HA expression vector or retroviral delivery of this transcription factor into the erythroleukemia cell line K562 resulted in an increase of fetal hemoglobin. The ␥-globin content of cells expressing gg1-vp64-HA showed up to 16-fold higher levels of fetal hemoglobin than the native K562 cell line. These transcriptional activators constitute a novel class of regulators of the globin locus that may be suitable for treatment of diseases arising from mutations in this locus such as sickle cell disease and thalassemic diseases.
Artificial transcription factors can be engineered to interact with specific DNA sequences to modulate endogenous gene expression within cells. A significant hurdle to implementation of this approach is the selection of the appropriate DNA sequence for targeting. We reasoned that a good target site should be located in chromatin, where it is accessible to DNA-binding proteins, and it should be in the close vicinity of known transcriptional regulators of the gene. Here we have explored the efficacy of these criteria to guide our selection of potential regulators of ␥-globin expression. Several zinc finger-based transcriptional activators were designed to target the sites proximal to the ؊117-position of the ␥-globin promoter. This region is proximal to the binding sites of known and potential natural transcription factors. Design and study of three transcription factors identified the potent transcriptional activator, gg1-VP64-HA. This transcription factor was able to interact directly with the ␥-globin promoter and upregulate expression of reporter gene constructs as well as the endogenous gene in a selective manner. Transfection of a gg1-VP64-HA expression vector or retroviral delivery of this transcription factor into the erythroleukemia cell line K562 resulted in an increase of fetal hemoglobin. The ␥-globin content of cells expressing gg1-vp64-HA showed up to 16-fold higher levels of fetal hemoglobin than the native K562 cell line. These transcriptional activators constitute a novel class of regulators of the globin locus that may be suitable for treatment of diseases arising from mutations in this locus such as sickle cell disease and thalassemic diseases.
The human ␤-globin locus is located on chromosome 11 and contains five homologous globin genes that are differentially expressed during development (Fig. 1 ). In the embryonic stage of development, the ⑀-gene is predominantly expressed. Its expression is replaced with ␥-globin during the fetal stage; ␥-globin forms tetrameric fetal hemoglobin (HbF), 1 consisting of two ␥-and two ␣-chains. Shortly after birth, the expression of ␥-globin starts to decline, and it is gradually replaced by ␤-globin, which forms ␣ 2 ␤ 2 , the adult version of hemoglobin (HbA). Transcriptional control of these genes is mediated by silencers and enhancers both within and flanking the genes in the locus (1) (2) (3) (4) (5) . Situated upstream of the genes is a locus control region (LCR) that is necessary for activation of the entire locus. The differential expression of the globin genes is thought to depend on physical competition of the genes for association with the LCR. This association is mediated by different transcription factors (6, 7) . Several genetic diseases are associated with defective ␤-globin expression, the most common being ␤-thalassemias and sickle cell disease. A feature common to both sickle cell disease and ␤-thalassemia is that disease can be mitigated by the production of the fetal globin chain ␥ that can serve to form ␣ 2 ␥ 2 or fetal hemoglobin HbF. One example of such protection from disease is the benign condition known as "hereditary persistence of fetal hemoglobin" (HPFH), which is characterized by an increase in the level of fetal hemoglobin. Fetal hemoglobin is normally 1-2% of the globin level, but in HPFH it can be increased up to 20%. Patients that have both SCD and HPFH typically have minimal symptoms of disease (8, 9 ). These observations have spurred studies to induce HbF expression for the treatment of SCD, and several potent compounds have been identified including hydroxyurea, butyrate, ribavirin, activin A, and 5-azacytidine (10) . Treatment with these compounds, however, produces a range of side effects. Another possible therapeutic intervention for patients suffering from SCD or thalassemia is to deliver globin genes directly (11, 12) or to impart continuous transcriptional activation of the endogenous HbF gene through gene therapy approaches. In contrast to treatment with blood transfusions or with compounds like hydroxyurea, these approaches would potentially allow for treatment of the diseases only once or rarely.
In this study, we have investigated the use of artificial transcription factors as a means of inducing ␥-globin expression. Phage-based selection and rational design have shown that Cys 2 -His 2 zinc fingers can be adapted to bind a wide variety of DNA sequences (13) (14) (15) (16) (17) (18) . Typically, a zinc finger domain recognizes three base pairs of DNA, and recognition of all possible DNA triplets therefore requires an alphabet of 64 different domains. Many such specific DNA-binding domains are now available (16 -18) . In contrast to most transcription factors that rely on dimerization of protein domains for extending protein-DNA contacts to longer DNA sequences, or addresses, simple covalent linkage of tandem repeats of the zinc finger domain allow for the recognition of longer asymmetric sequences of DNA. Three to six domains are typically fused to yield a DNA-binding domain (DBD) recognizing 9 -18 bases of DNA. These polydactyl zinc finger proteins typically target DNA sequences with high affinity and specificity. When fused to activation or repression domains, these proteins become potent regulators of the transcriptional activity of the target gene. One activation domain that has shown promise as a potent activator when fused to zinc finger protein is the VP64 domain. The VP64 domain consists of a tetrameric repeat of the minimal activation domain (amino acids 437-447) of the herpes simplex protein VP16 (19) .
Artificial transcription factors have been applied to regulate endogenous gene expression in a number of instances (20 -25) . A significant obstacle to creating productive artificial transcription factors is the selection of the DNA site to be targeted. We reasoned that a good target site should be located in chromatin, where it is accessible to DNA-binding proteins and it should be in the close vicinity of known transcriptional regulators of the gene. There have been reports correlating the ability of designed three-finger proteins in regulating gene expression to the location of their target sites in accessible chromatin structures (26, 27) . Accessible target sites may be located in the linker region between positioned nucleosomes and are sensitive to micrococcal nuclease digestion or are hypersensitive to DNase I. In the promoter region of the human ␥-globin genes, no DNase I-hypersensitive sites have been found; nor have the positions of nucleosomes been determined. However, the promoter sequences required for the ␥-globin expression have been studied extensively. These sequences may represent the binding sites for transcriptional regulators and thus are probably located in accessible chromatin regions. Therefore, we chose target sequences next to known cis-regulatory sites with our zinc finger proteins. Target sites immediately adjacent to the known cis-regulatory sites may be advantageous in gene regulation as well. It has become clear that in a gene regulation event, both transcriptional activation functions and repression functions are imposed on the promoter, and the regulatory outcome depends on the relative strengths of these opposing functions (28) . Closely positioned activators on the promoter often act synergistically to boost transcription. Therefore, by following these guidelines, it may be possible to effectively select target sites that are both accessible and supportive of synergism within activators.
Here we have studied the potential of these design selection criteria for the development of artificial transcription factors for the targeted up-regulation of ␥-globin expression. We have analyzed the ability of our designed transcription factors to activate transcription of reporter constructs and the endogenous ␥-globin gene in the human erythroleukemia cell line K562.
MATERIALS AND METHODS

Assembly of the DNA-binding Domains and Construction of Expression Vectors for the Transcription
Factors-Recognition helices for fingers recognizing 5Ј-GNN-3Ј or 5Ј-ANN-3Ј triplets of DNA have been reported (16 -18) . Assembly of DBDs, each consisting of six zinc finger domains fused head-to-tail, were performed as previously described (17, 29, 30) and were subcloned into the bacterial expression vector pMAL-CSS, a derivative of the bacterial expression vector pMAL-c2 (New England Biolabs, Beverly, MA). The DBDs were subsequently subcloned into pcDNA3-VP64-HA, as described elsewhere (29) , using the two SfiI restriction sites. The resulting plasmids each express a fusion protein with an N-terminal DBD followed by the transcriptional activator domain VP64 and a C-terminal hemagglutinin (HA) decapeptide tag.
Expression, Purification, and DNA Binding Characterization of the DBD-The DBD were expressed as maltose-binding protein (MBP) fusion proteins from the pMAL-CSS constructs. The proteins could be purified to Ͼ90% purity using the Protein and Fusion purification system (New England Biolabs) as per the manufacturer's protocol, except that the running buffer in the column purification was zinc buffer A (10 mM Tris-HCl, pH 7.5, 90 mM KCl, 1 mM MgCl 2 , 90 M ZnCl 2 ) supplemented with 1% bovine serum albumin and 5 mM dithiothreitol. Protein purity was analyzed by separating eluted proteins on a 15% SDS-polyacrylamide gel. Protein concentrations were determined using the Bio-Rad protein assay and was compared with a bovine serum albumin standard. The dissociation constant for the DBD and its target sequence was determined using an electrophoretic mobility shift assay (EMSA) essentially as described (31) .
Construction of a Dual Luciferase Reporter Plasmid-The ␥␤-2luc plasmid was constructed by fusing the ␥-and ␤-globin promoters to the firefly and Renilla luciferase genes, respectively. Others have reported a similar reporter vector (32) . Firefly luciferase was isolated from the pGL3-basic vector (Promega, Madison, WI) by digestion with HindIII and SalI. It was inserted into pRL-null (Promega) that had been cut with the same enzymes, resulting in the plasmid p-2luc. The ␤-globin promoter from position Ϫ206 to ϩ47 relative to the start of transcription was PCR-amplified using the primers ␤-3b (5Ј-GAACTGCAGTCT-GTTTGAGGTTGCTAGTGAACACAG-3Ј) and ␤-5f (5Ј-GGAATTCAAG-AGATATATCTTAGAGGGAGGGCTG-3Ј). The resulting PCR product and the vector p-2luc were cut with EcoRI and PstI and ligated to give the vector ␤R-2luc. The ␥-globin promoter from position Ϫ206 to ϩ47 relative to the start of transcription was PCR-amplified using the primers ␥-3b (5Ј-CCCAAGCTTGGACTAGGAGCTTATTGATAATCTCAG-3Ј) and ␥-5f (5Ј-TCACCGCGGGCCCCTTCCCCACACTATCTCAATG-3Ј) and was cut with SacII and HindIII. The DNase I-hypersensitive sites 2 and 3 (LCRHS3 and LCRHS2) comprise bases 8489 -8865 and 4425-4823 of the human ␤-globin locus. LCRHS2 was PCR-amplified using LCRHS2-3b (5Ј-TCCCCGCGGCTAGAATATGTCACATTCTGT-CTCAGG-3Ј) and LCRHS2-5f (5Ј-GAGGGTACCGCTTCAGTTTTTCC-TTAGTTCCTGTTAC-3Ј), and was cut using KpnI and SacII. LCRHS3 was PCR-amplified using LCRHS3-3b (5Ј-CGGGGTACCCTGGGGGT-ATAGGGGAGCAGTCCCATG-3Ј) and LCRHS3-5f (5Ј-CCGCTCGAGC-TGTGGATAAAGGAGACAGCCATGAAG-3Ј) and was cut using XhoI and KpnI. The vector ␤R-2luc was cut using XhoI and HindIII. Cut fragments corresponding to ␤R-2luc, LCRHS2, LCRHS3, and ␥-globin promoter were ligated, resulting in the vector ␥␤-2Luc.
Cell Lines-All cell culture experiments were performed using the erythroleukemia cell line K562 (ATCC number CCL-243). Cells were maintained at a density of Ͻ4 ϫ 10 5 /ml in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal calf serum (Hyclone, Logan, UT) and 1% antibiotic antimycotic mixture (Invitrogen). Transfection of DNA constructs to the cells was mediated by PLUS Reagent and Lipofectamine TM (Invitrogen).
Analysis of the Transcription Factors (TFs) Using a Reporter Assay-
For each sample, different amounts of the pcDNA-DBD-VP64-HA construct (2-50 ng) was mixed with 50 ng of the reporter plasmid ␥␤-2luc and 50 ng of the CMV-LacZ reporter plasmid. The amount of plasmid in each sample was adjusted to a total of 150 ng by the addition of the starting pcDNA3.1 plasmid. Each sample was then transfected into 50 ϫ 10 3 K562 cells in a 96-well plate format. As a control, hemin (Sigma) was used in different concentrations to treat K562 cells that had been transfected with 50 ng of ␥␤-2luc and 50 ng of CMV-LacZ. Extracts from cells transfected with TFs were prepared ϳ72 h posttransfection, and extracts from cells treated with hemin were prepared ϳ96 h post-transfection. Growth medium was changed on hemin treated cells 48 and 72 h after transfection. The cell lysates were analyzed for their content of firefly and Renilla luciferase by the DualLuciferase reporter assay system (Promega). The cell lysates were also analyzed for their content of ␤-galactosidase using the Galacto-Light Plus™ reporter system (Tropix, Bedford, MA). The luciferase values could subsequently be normalized to the ␤-galactosidase activity.
Theoretical Analysis of gg1 Specificity-The programs used for the theoretical analysis of the ␤-globin locus were BLASTN with the option, "Search for short, nearly exact matches" (available on the World Wide Web at www.ncbi.nlm.nih.gov/BLAST/) and Fuzznuc, written by Alan Bleasby (available on the World Wide Web at www.hgmp.mrc.ac. uk/Software/EMBOSS/Apps/fuzznuc.html).
Regulation of Endogenous ␥-Globin Expression-K562 cells (1.2 ϫ 10 7 ) were co-transfected with 12 g of pcDNA-gg1-VP64-HA or 12 g of pcDNA3.1 (Invitrogen) and 3 g of pLEGFP (BD Biosciences) and grown for 72 h with one exchange of growth medium after 48 h. The cells were subsequently sorted in a FACSvantage DiVa (BD Biosciences), and 10% of the cells with the highest enhanced green fluorescent protein signal were collected and analyzed by Western blotting.
Retroviral expression of gg1 transcription factors was accomplished by subcloning gg1 into pMX-effector vectors. Virus was prepared and delivered as described (20, 25) . Selection of cell lines with stable expression of gg1-VP64-HA was performed by growing cells transfected with pcDNA-gg1-VP64-HA for 5 days, after which Geneticin G418 (Invitrogen) was added to a concentration of 250 g/ml. Cells were maintained for an additional 14 days, after which individual surviving cells were allowed to expand in the presence of 250 g/ml Geneticin, and the resulting clonal populations were analyzed.
Analysis of HbF Content by Western Blotting-Samples were collected by centrifugation and resuspended in reporter lysis buffer (Promega, Madison, WI). Cells were incubated on ice for 20 min followed by freezing at Ϫ80°C. Cells were thawed on ice, and solid material was removed by centrifugation. Cell lysate containing 10 g of protein was separated on a 15% SDS-polyacrylamide gel followed by blotting to a nitrocellulose filter. The filter was probed with a mouse monoclonal anti-HbF antibody (Caltag Laboratories, Burlingame, CA) at 0.5 g/ml in Tris-buffered saline supplemented with 0.1% Tween 20. The filters were developed using the ECLϩplus kit (Amersham Biosciences).
DNase I Footprinting-For DNase I footprinting, 100 pmol of the oligonucleotide fp-1 (5Ј-TGTCTGAAACGGTCCCTGGCTAA-3Ј) was end-labeled with 32 P by incubation with 1 l [␥-32 P]ATP (8000 Ci/mmol) and 10 units of T4 polynucleotide kinase (Roche Applied Science) in T4 polynucleotide kinase buffer for 60 min at 37°C. Fp-1 was subsequently used with the oligonucleotide fp-2 (5Ј-ACTGCTGAAGGGTGCTTCCTT-3Ј) in a PCR. The PCR mixture was separated on a nondenaturing polyacrylamide gel, and the band corresponding to the 180-bp fragment encompassing the gg1-binding site was recovered. For each footprinting reaction, the following was mixed: ϳ1 ng of 32 P-labeled PCR product and from 100 nM to 1 pM MBP-gg1 in 390 l of zinc buffer A supplemented with 0.5 mM dithiothreitol. The reactions were equilibrated overnight at 4°C and then digested with DNase I. The digested samples were separated on a 6% polyacrylamide gel containing 8.3 M urea, 88 mM Tris borate (pH 8.3), and 2 mM EDTA. The gel was developed using a phosphor imager screen and subsequently visualized in a Molecular Dynamics SF phosphor imager.
Chromatin Immunoprecipitation (ChIP)-ChIP assays were performed as described with the following modifications (25, 33) . Nuclei from a minimum of 10 7 cells/immunoprecipitation were cross-linked, isolated, and sonicated to produce 500-bp chromatin fragments. TF ZF -chromatin complexes were captured by centrifugation using 10 l of ZF antibody or no antibody and lyophilized StaphA cells (Calbiochem), washed extensively and analyzed by PCR for 35 cycles using the forward 5Ј-GACTGAATCGGAACAAGGCAAAG-3Ј and reverse 5Ј-TGTCCTCCTCTGTGAAATGACCC-3Ј primers producing a 338-bp PCR fragment containing the gg1 target site in the human ␥-globin gene locus. As negative control, PCR primers amplifying the ICAM-1 promoter were used as described (25) .
Analysis of HbF Content by Flow Cytometry-Samples of ϳ5 ϫ 10 5 cells were collected and washed with 100 l PBS supplemented with 0.1% bovine serum albumin (PBS-B). Cells were fixed by incubation for 10 min in 0.05% glutaraldehyde (Sigma) in PBS-B followed by washing with PBS-B. After fixation, cells were permeabilized by incubation with 0.1% Triton X-100 (Sigma) in PBS-B for 3 min followed by washing with PBS-B. Samples were stained by incubation with R-phycoerythrinconjugated mouse monoclonal antibody against fetal hemoglobin (PEHbF) (Caltag Laboratories) for 45 min at a working concentration of 2.5 g/ml in PBS-B followed by washing with PBS-B. Cells stained for HbF content were analyzed by flow cytometry using a FACScalibur instrument (BD Biosciences).
Analysis of mRNA Levels of gg1-VP64 Using RT-PCR and Real Time PCR-Samples containing 10
6 cells were collected followed by RNA extraction using the TriReagent kit (Molecular Research Center, Cincinnati, OH). After the last precipitation step, the pellet containing pure RNA was resuspended in 150 l of water and frozen at Ϫ80°C until analyzed. For RT-PCR analysis of gg1-VP64-HA, 2.5 g of RNA was annealed with an oligo(dT) primer and then reverse transcribed with the Superscript kit (Invitrogen). For each RT-PCR analysis, 5% of the synthesized cDNA was used as a template in a nested PCR. The first PCR was with the outer primers TF-1 (5Ј-ACTGCCGCGACCTTGCT-3Ј) and TF-2 (5Ј-CGGAACGTCGTACGGGTAGTT-3Ј) using the following program: denaturation (94°C, 30 s) followed by 25 cycles of amplification (94°C, 30 s; 55°C, 30 s; 72°C, 60 s) and ending with a final extension step (72°C, 7 min). 1 l of the outer PCR was used as a template for the inner PCR with the primers TF-3 (5Ј-TTCTCCCG-CAGCGATCAC-3Ј) and TF-4 (5Ј-CCAAAGCACCTGGGTCTGA-3Ј). The PCR program for the inner PCR was the same as for the outer, except that the 72°C extension step in each amplification cycle was for 30 s instead of 60 s. RT-PCR of GADPH was performed using gadph-f (5Ј-CCATGTTCGTCATGGGTGTGA-3Ј) and gadph-r (5Ј-CATGGACTGTG-GTCATGAGT-3Ј). The PCR program used was the same as the inner PCR of gg1-VP64-HA.
The amount of ␥-globin was quantified by a real time PCR analysis of the synthesized cDNA. The analysis was carried out on an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) according to the manufacturer's protocols, using SYBR Green dye for detection of synthesized amplicons. The primers used for ␥-globin were ggrt-f (5Ј-GACAAGCTGCATGTGGATCCT-3Ј) and ggrt-r (5Ј-CCGAAATGGATTGCCAAAAC-3Ј). This primer pair gave an amplicon that extended over the splice junction between exon 2 and exon 3. The primers used for GADPH were gadph-f and gadph-r. All values for the ␥-globin mRNA were normalized against the amount of GADPH mRNA.
Immunocytochemical Cellular Localization of gg1-VP64-HA and HbF-Cells were seeded on poly-L-lysine-coated Lab-Tek cover glasses and incubated for 30 min. Cells were washed with copious amounts of PBS, incubated with 4% paraformaldehyde for 20 min, washed again, and incubated in a humidifying chamber at room temperature for 1 h with primary antibody mixture of biotinylated rat anti-HA monoclonal antibody (5 g/ml) (Roche Applied Science) and mouse anti-human HbF monoclonal antibody (Caltag Laboratories). The cells were then stained for 1 h at room temperature with the mixture of Cy5-conjugated donkey anti-mouse IgG polyclonal antibodies and streptavidin/rhodamine Red-X (both from Jackson Immunoresearch, West Grove, PA) diluted to 1:100 in PBS-B, 0.1% saponin. Finally, the cells were incubated with DAPI solution for 5 min, washed with PBS, and covered with SlowFade antifade reagent. Three-color (DAPI, rhodamine Red-X, and Cy5) threedimensional data sets were collected with a DeltaVision system (Applied Precision, Issaquah, WA); this consisted of an Olympus IX-70 fluorescence microscope, a motorized high precision xyz stage, a 100-watt mercury lamp, and a KAF1400 chip-based cooled charge-coupled device camera. Exposure times were 0.2-0.5 s (2-binning), and images were obtained with a ϫ60 oil objective. Three-dimensional reconstruction was generated by capturing 150-nm serial sections along the z axis. Images were deconvolved (based on the Agard-Sadat inverse matrix algorithm) and analyzed with softWorX version 2.5.
RESULTS
Targeting the ␥-Globin Promoter with Designed DNA-binding Domains-We designed and assembled the genes encoding three hexameric zinc finger-based DBDs to interact with the A ␥-and G ␥-globin promoters (henceforth referred to as the ␥-globin promoter). These DBDs, called gg1, gg2, and gg3, were designed to interact with the ␥-promoter in a region where other cis-acting TFs bind. Their predicted sites of interaction with the ␥-promoter and the sites of binding of the endogenous ␥-globin transcriptional activators FKLF and FKLF-2 are shown in Fig. 1A . After assembly, the DBDs were expressed in Escherichia coli as a fusion to MBP, and crude extracts from the cell cultures were analyzed for DNA binding in a sandwich enzyme-linked immunosorbent assay experiment. All three were found to bind strongly and specifically to the 18-base pair target DNA sequences for which they were designed (data not shown). The MBP-DBD fusion proteins were readily purified to homogeneity on amylose resin. The dissociation constants for the purified MBP-DBD fusion proteins and their target sequences were determined in an electrophoretic mobility shift assay, and the results are listed in Table I . The dissociation constant for gg1 and its target sequence was 0.7 nM. In contrast, the dissociation constants for gg2 and gg3 were 5.3 and 5.4 nM, respectively, almost 10 times higher than that for gg1.
Analysis of the TFs Using a Reporter Assay-Transcription factors were prepared from the three zinc finger proteins through fusion with the VP64 activation domain and were expressed using the expression vector pcDNA-VP64-HA. The resulting plasmids expressed transcription factors consisting of an N-terminal zinc finger protein fused to the domain VP64 and a C-terminal HA decapeptide tag that facilitates tracking of the expressed protein (Fig. 1B) . In order to analyze the ability of the designed TFs to activate transcription of the ␥-globin gene, a reporter vector ␥␤-2luc was constructed. The ␤-globin promoter was incorporated into the reporter vector in order to assess the specificity of gene activation. The ␥␤-2luc vector is shown in Fig. 2A . The vector encodes the ␥-globin promoter fragment sequence from Ϫ206 to ϩ47 relative to the start of transcription and drives expression of the firefly luciferase gene. The ␤-globin promoter fragment consists of the sequence from Ϫ206 to ϩ47 relative to the start of transcription and drives expression of the Renilla luciferase gene. Also included in ␥␤-2luc were the DNase I-hypersensitive sites 2 and 3 from the ␤-globin LCR. This portion of the LCR contains enhancer elements important for high level activation of the entire ␤-globin locus (34) .
Vector DNAs expressing the transcriptional activators were co-transfected with ␥␤-2luc into K562 cells. The amount of expressed firefly and Renilla luciferase was measured 72 h post transfection, and the results are plotted in Fig. 2 , B and C, as a function of the amount of transfected expression vector. Included in the experiment was a control that expressed e2c-VP64-HA (29) . This transcriptional activator was not predicted to interact with either the ␥-or the ␤-promoters specifically. As a control, K562 cells transfected with ␥␤-2luc were stimulated with hemin at different concentrations. There was a dose-dependent response for both the ␥-globin and ␤-globin promoters (data not shown).
gg1-VP64-HA was the strongest transcriptional activator, and luciferase expression was increased 47-fold over background at the highest concentration of transfected plasmid (Table II) . By contrast, gg2-VP64-HA and gg3-VP64-HA failed to activate luciferase expression of the reporter construct even at the highest plasmid concentrations. The negative control activated luciferase expression slightly. Hemin could activate this reporter construct moderately and had a 22-fold up-regulation of luciferase expression at the highest concentration relative to untreated cells. To examine the specificity of gg1-VP64-HA in this reporter assay, we created a reporter construct containing two mutated sites within the designed target site of gg1, A9G and G12T, but otherwise identical to ␥␤-2luc. These mutations were designed to compromise interactions of the third and the fourth fingers of the polydactyl zinc finger protein with their target sites. Indeed, these mutations destroyed the ability of gg1-VP64-HA to activate the reporter gene, whereas a reporter construct displaying only the G12T mutation was activated at an intermediate level (data not shown).
To analyze whether the TFs could interact with the ␤-globin promoter and activate ␤-globin expression, we also measured the levels of Renilla luciferase in the transfected cells. gg1-VP64, gg2-VP64-HA, and gg3-VP64-HA induced Renilla luciferase expression 4-, 1-, and 1-fold relative to untreated cells at the highest plasmid concentrations. This was similar to the activation observed with negative controls. Hemin activated luciferase expression 2-fold.
DNase I Footprinting of gg1-Since gg1-VP64-HA was the only TF that could activate expression by interaction with the ␥-globin promoter in the reporter assay, it was further analyzed. To ascertain that gg1 bound to the predicted target sequence within the ␥-globin promoter, a DNase I footprinting experiment was performed with a stepwise dilution series of MBP-gg1 from 100 nM to 1 pM; the resulting gel is shown in Fig.  3 . This study demonstrated that gg1 bound to the 18-bp site targeted within the ␥-globin promoter.
Theoretical Analysis of gg1 Specificity-The LCR and proximal promoters (from Ϫ2000 relative to the start of transcription up to and including the untranslated region) of all genes in the ␤-globin locus were analyzed to identify putative gg1 interaction sites using BLASTN and Fuzznuc. A BLASTN search did not identify any sites within the LCR or promoters with more than 8-base homology to the predicted gg1 binding site, except for the two targeted sites within the A ␥ and G ␥ promoter. Several sites with 8-base or lower homology were found evenly dispersed throughout the LCR and promoters. Fuzznuc, which allows any base mismatch within the search sequence, did not FIG. 1. A (top) , the 80-kb ␤-globin locus located on chromosome 11. A (bottom), a detailed map of the A ␥-promoter from position Ϫ145 to Ϫ87 relative to the start of transcription. The binding sites of gg1 and gg2 (binding the bottom strand) as well as gg3 (binding the top strand) are shown as arrows. B, schematic view of how the artificial transcription factors are composed. The DBD is at the N terminus followed by VP64, and the HA tag is located at the C terminus. identify any sequences within the LCR or promoters with less than a 7-base mismatch. Fuzznuc identified several sequences with 7-base or more mismatches dispersed throughout the LCR and promoters.
Regulation of Endogenous ␥-Globin Expression in Transfected Cells-Encouraged by the high level of activation of the ␥-globin promoter in the gg1-VP64-HA reporter assay, we analyzed transcription of the endogenous ␥-globin gene in the presence of this TF. The erythroleukemia cell line K562 was co-transfected with pcDNA-gg1-VP64-HA and pLEGFP, or pcDNA3.1 (empty vector) and pLEGFP, followed by cultivation for 96 h. The cells were subsequently sorted, and the 10% with the highest enhanced green fluorescent protein values were collected. Intracellular lysates from the collected cells were analyzed for HbF content by Western blotting (Fig. 4A) . Densitometric quantification of the bands in Fig. 4A showed 8-fold higher content of HbF in cells transfected with the transcriptional activator than those transfected with the empty vector.
Chromosomal Integration of the Designed TF-To characterize the K562 cells expressing gg1-VP64-HA in more detail, several clones with genomic integration of the pcDNAgg1-VP64-HA construct were generated. Genomic clones were prepared by transfection of pcDNA-gg1-VP64-HA into K562 cells followed by selection with Geneticin G418. Individual surviving clones were expanded. In order to quantify the -fold of up-regulation of HbF in these clones, intracellular lysates were prepared and analyzed for HbF levels by Western blotting (Fig. 4b) . The level of HbF in these clones varied from 7-to 16-fold higher than that of untransfected K562 cells as determined by densitometric quantification. One of these clones, labeled D8, was used for further studies.
Analysis mRNA transcription, total RNA from normal K562 cells and from the stably transfectant clone D8 was collected and converted to cDNA. Analysis for the presence of gg1-VP64-HA mRNA was performed using these cDNA samples as template in a nested RT-PCR with gg1-VP64-HA-specific primers. The gg1-VP64-HA mRNA was indeed present in the D8 cells (Fig.  5A, lane 2) . No gg1-VP64-HA mRNA was detected in the sample from the normal K562 cells (Fig. 5A, lane 1 ). An mRNA sample from the D8 clone where no reverse transcriptase was added during cDNA synthesis was also negative (Fig. 5A, lane  3) . Hence, the band in Fig. 5A , lane 2, does not originate from a genomic DNA template and is indeed the amplification of a reverse transcribed mRNA. The relative amounts of ␥-globin mRNA were determined by real time PCR using the cDNA samples. This showed that the ␥-globin mRNA levels were 2.5 times higher in the D8 clone compared with native K562 cells.
Visual and Flow Cytometric Analysis of Retrovirally Transduced Cells and the D8 Cell Line-In order to further study targeting and the ability of gg1-based transcription factors to directly regulate the endogenous ␥-globin gene, gg1 was subcloned into pMX retroviral vectors and expressed as a fusion to either the activation domain VP64 or the transcriptional repression domain Krü ppel-associated box (KRAB) (29, 35) . The effect of gg1 transcription factors was considerable in retrovirally transduced K562 cells in both activation and repression of ␥-globin expression. Visual inspection of the cell pellet of retrovirally transduced cells and the cell pellet of native K562 cells showed that the cells transduced with the VP64 activator were significantly more red-colored, whereas the cells transduced with the KRAB repressor were more opaque than the native cells (Fig. 6A) . The variation in red coloration of the cells is probably due to differing levels of HbF. The cells were also stained with an antibody specific for HbF and analyzed in a flow cytometer (Fig. 6B) , where the HbF level was reduced by 90% in the repressor-transduced cells and increased 14-fold with VP64 activator-transduced cells (Fig. 6B) .
In comparison, the D8 clonal line stably expressing the activator had a 8-fold higher amount of HbF than native K562 cells as determined by fluorescence-activated cell sorting analysis and also demonstrated a more intense red color in the cell pellet. Fluorescence-activated cell sorting determination of HbF content was comparable with the level of up-regulation determined by Western blotting (10-fold) . The D8 clone could be cultivated for over 3 months without any apparent loss of HbF expression, as judged by periodic visual inspection of pelleted cells and flow cytometric analysis.
In Vivo Binding of Transcription Factors as Determined by Chromatin Immunoprecipitation-A chromatin immunoprecipitation (ChIP) experiment was performed to further establish the direct interaction of gg1 transcription factors with the ␥-globin promoter site in vivo (Fig. 6C) . A chromatin fragment comprising the ␥-globin promoter site was efficiently crosslinked by the gg1-VP64-HA and gg1-KRAB-HA proteins expressed in K562 cells and co-immunoprecipitated with a polyclonal antibody raised specifically against the framework of our designer zinc finger domains (25) . No immunoprecipitated DNA fragment was detected by PCR using native K562 cells or without the addition of the antibody. This demonstrates that the immunoprecipitated complex was only formed with our artificial transcription factors and not with endogenous zinc finger-containing factors and that our designed transcription factors interact with the ␥-globin promoter site directly in vivo.
Analysis of Expression of gg1-VP64-HA and HbF Using Deconvolution Fluorescence Microscopy-Individual cells from the stably transfected clone D8, normal K562 cells, and K562 cells treated with the HbF inducer hemin were studied in a deconvolution microscope. Cell samples were collected and permeabilized with saponin. This was followed by staining with DAPI, an anti-HA monoclonal antibody, and an anti-HbF monoclonal antibody, which interact with the cell nucleus, gg1-VP64-HA, and HbF, respectively. The cells were subsequently visualized in a deconvolution microscope, and the maximal projections of three-dimensional datasets are shown in Fig. 7 . Cells of the D8 clone and of hemin-stimulated cells contained an increased level of HbF compared with the K562 cells (Fig. 7,  compare g and h with i) . Fig. 7 also shows that the zinc finger was present only in the D8 clone (Fig. 7, compare e with d and  f) . In addition, HbF was located in the cytoplasm of the cells, and gg1-VP64-HA was located in the nucleus of the cells (Fig.  7, j, k, and l) . 
DISCUSSION
We have designed and analyzed three zinc finger-based transcription factors for transactivation of the ␥-globin gene. When identifying possible target sites within the promoter for TF interaction, several issues were taken into consideration. One important issue was the distance of the TFs from the start of transcription. We were aided in this case by considerable data on sequences within the ␥-globin promoter where endogenous enhancers and silencers interact. For example, the two cis-acting ␥-globin activators FKLF and FKLF-2 interact with the Ϫ145 CACCC-box (36, 37) . This sequence has been shown to be important for high level activation of the ␥-globin promoter (38) . The Ϫ112 and Ϫ85 CCAAT-boxes constitute a minimal promoter and can direct transcription of a low level of the ␥-globin gene (39) . Mutations in either of the CCAAT-boxes decrease the activity of the promoter (40) . Also, a G to A mutation at position Ϫ117 has been shown to increase expression of ␥-globin in cases of hereditary persistence of fetal hemoglobin (41) (42) (43) . The molecular mechanism responsible for HPFH (Ϫ117 G 3 A) remains unclear. However, a study analyzing DNA-protein interactions in the ␥-globin promoter in vivo revealed that an unknown protein interacts with the promoter in the CCAAT-box situated next to position Ϫ117 (44). It is possible that this DNA-protein interaction is affected by the mutation. We therefore reasoned that this portion of the promoter would be accessible to artificial transcription factors and would be at a suitable distance from the start of transcription. Another issue was target site accessibility. We reasoned that the appearance of the Ϫ145 CACCC-box and the Ϫ112 and Ϫ85 CCAAT-boxes in this region implied that the sequences would be accessible to designed TFs.
We were able to show that the DNA-binding domains of each of the three TFs constructed were able to bind to double-stranded hairpin DNA corresponding to sequences in the ␥-globin promoter with low to subnanomolar affinity. When analyzed for the ability to interact with the full ␥-globin promoter and induce expression of luciferase in a reporter construct, however, only one of them (gg1-VP64-HA) could induce expression above the level of the controls. Furthermore, the activity of this transcription factor was sensitive to mutations introduced into its targeted binding site. It may be that gg2-VP64-HA and gg3-VP64-HA failed to activate transcription, since their binding sites are not at the correct distance from the start of transcription. We note that the binding site of gg1-VP64-HA is closer to the CACCC-boxes where FKLF and FKLF-2 bind than the sites of the inactive designed TFs. The FKLF and FKLF-2 sites may have evolved to be at an optimal distance from the start of transcription. Another reason why gg1-VP64-HA activated transcription whereas the other TFs did not may be that the affinity of gg2-VP64-HA (5.3 nM) and gg3-VP64-HA (5.4 nM) for their respective target DNA sequences was almost 10 times weaker that the affinity of gg1-VP64-HA for its target sequence (0.7 nM). A correlation between transcription factor affinity and activation or repression activity has been noted in studies targeting the erbB-2 gene and the HIV-1 long terminal repeat (20, 45) .
We demonstrated significant induction of endogenous ␥-globin expression in the erythroleukemia cell line K562 upon transfection or retroviral transduction of cells with gg1-VP64-HA. To demonstrate that the regulation of ␥-globin expression by gg1-VP64-HA was direct, we examined the ability of gg1-KRAB, a designed repressor bearing the same DNA recognition domain, to repress transcription of the same gene. We demonstrated not only activation of ␥-globin with the retrovirally delivered activator but also near complete repression of ␥-globin expression upon delivery of the repressor to K562 cells, providing strong evidence for direct target ␥-globin gene regulation as opposed to nonspecific binding of the transcription factor that might lead to erythroid differentiation of K562 cells and subsequent indirect up-regulation of ␥-globin gene expression. Furthermore, the direct in vivo interaction of our designed transcription factors with the ␥-globin promoter was demonstrated in chromatin immunoprecipitation experiments.
The level of HbF increased 7-16-fold in K562 cells stably transfected or retrovirally transduced with gg1-VP64-HA. This level of induction is higher than values reported by others in studies of hydroxyurea-treated K562 cells (46) . It is not presently known whether the level of HbF increase in K562 cells induced by the transcription factor gg1-VP64-HA will be sufficient to ameliorate symptoms of SCD or thalassemic diseases in human patients. Studies performed on patients suffering from SCD have shown that normal levels of HbF vary greatly within the population (from 2-32%) (47). However, major organ failure, stroke, and aseptic necrosis, all leading to premature death, seem to be ameliorated at levels of HbF higher than 10% (47) , and an even higher corrective effect is seen at HbF levels higher than 20%, which significantly reduces SCD caused hospitalization (48) . Thus, we are hopeful that our designed transcription factor could have a favorable effect on SCD patients.
There are several potential ways of delivering this TF to affected patients. One strategy could include collection of hematopoietic stem cells from the patient affected by SCD or a thalassemic disease followed by retroviral infection with virions carrying the gene encoding gg1-VP64-HA. Transduced cells could then be delivered back to the individual. This strategy may overcome problems with graft versus host disease and difficulties with finding a suitable donor, two major obstacles associated with hematopoietic stem cell transplantation. The potential use of zinc finger-based TF therapeutics agents has been demonstrated in murine models (22, 49) . We expect that the TFs described in this paper will be nontoxic, since the cells maintain the same doubling time when expressing the TF (data not shown). By utilizing information regarding the binding of proximal native transcription factors coupled with genetic information, we have been able to design a transcription factor that efficiently up-regulates transcription of endogenous ␥-globin in the erythroleukemia cell line K562, leading to an increased content of HbF in the cells. This lays the foundation for experiments in disease systems of SCD and thalassemia in animal models as well as gene therapy experiments with patients suffering from these diseases.
